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Cellular disease modelThe study of mechanisms that underlie Parkinson's disease (PD), as well as translational drug development,
has been hindered by the lack of appropriate models. Both cell culture systems and animal models have
limitations, and to date none faithfully recapitulate all of the clinical and pathological phenotypes of the
disease. In this review we examine the various cell culture model systems of PD, with a focus on different
stem cell models that can be used for investigating disease mechanisms as well as drug discovery for PD. We
conclude with a discussion of recent discoveries in the ﬁeld of stem cell biology that have led to the ability to
reprogram somatic cells to a pluripotent state via the use of a combination of genetic factors; these
reprogrammed cells are termed “induced pluripotent stem cells” (iPSCs). This groundbreaking technique
allows for the derivation of patient-speciﬁc cell lines from individuals with sporadic forms of PD and also
those with known disease-causing mutations. Such cell lines have the potential to serve as a human cellular
model of neurodegeneration and PD when differentiated into dopaminergic neurons. The hope is that these
iPSC-derived dopaminergic neurons can be used to replicate the key molecular aspects of neural
degeneration associated with PD. If so, this approach could lead to transformative new tools for the study
of disease mechanisms. In addition, such cell lines can be potentially used for high-throughput drug
screening. While not the focus of this review, ultimately it is envisioned that techniques for reprogramming
of somatic cells may be optimized to a point sufﬁcient to provide potential new avenues for stem cell-based
restorative therapies.
© 2009 Published by Elsevier B.V.1. Introduction
Parkinson's disease (PD) is one of the most common neurodegen-
erative diseases of aging. Approximately 1–2% of the population over
65 years is affected by this disorder, and it is estimated that the
number of prevalent cases of PD will double by the year 2030 [1].
Thus, there is an urgent need to better understand this neurodegen-
erative disease and to develop new therapies, particularly those aimed
at disease modiﬁcation and even prevention.
Classical clinical features of PD include rest tremor, bradykinesia
(slowness of movement), rigidity and loss of postural stability.
Importantly, it is now clear that a wide variety of other clinical
manifestations accompany the disease, many of which are non-
motor, ranging from autonomic dysfunction to dementia [2]. Classic
neuropathologic features include the loss of dopaminergic neurons
in the substantia nigra and the presence of neuronal intracytoplasmic
and intra-axonal inclusions known as Lewy bodies and Lewy
neurites, respectively. New immunohistochemical staining tech-
niques have shown that the neuritic pathology is widespread+1 408 734 8544.
).
lsevier B.V.throughout the central and peripheral nervous system, thus ex-
plaining many of the non-dopaminergic features of the disease
[3,4].
The mechanisms that underlie neuronal dysfunction and eventual
cell death in PD remain unknown although theories abound, ranging
from oxidative stress and inﬂammation to abnormal protein fold-
ing and “toxic” aggregation. However, one of the major barriers to
research on disease mechanisms has been the inaccessibility of
targeted living neuronal populations from patients with the disease
and consequent reliance on postmortem samples. Unfortunately,
primary cells from postmortem brain samples have short life-spans
in vitro; although some postmortem and biopsy tissue preparations
from rodent and human brain can provide stem/progenitor cell
populations that have the potential for drug screening or other
therapeutic applications [5–8]. Nevertheless, PD itself effectively
ablates the very cell type of interest—the midbrain dopamine neuron.
Thus, to date, it has been difﬁcult to performmeaningful experiments
on disease-affected human neural tissues. To overcome this barrier,
early studies relied on embryonic midbrain cultures from rat to
model the dopaminergic system. In these cultures, however, only a
minor subset of neurons (1–2%) were dopaminergic and showed
immunoreactivity for tyrosine hydroxylase (TH); none-the-less
investigators put these cultures to use as an initial system to study
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develop dopaminergic cell lines have expanded dramatically, largely
driven by the interest in obtaining cells that could be used for
grafting into the adult human brain to treat the symptoms of PD.
Importantly, speciﬁc markers have been established to characterize
dopaminergic neurons, including TH and aromatic L-amino acid
decarboxylase (AADC), both of which are involved in the synthesis of
dopamine (DA). The dopamine transporter (DAT) and the vesicular
monoamine transporter (VMAT2) are indispensable for DA neuro-
transmission and are also excellent markers for DA neurons.
Transcription factors that indicate midbrain speciﬁcity include
nuclear receptor related 1 (Nurr1) and paired-like homeodomain
transcription factor 3 (Pitx3). Morphologically midbrain dopaminer-
gic neurons exhibit long branched neurites with varicosities. Their
terminals release DA after potassium exposure which can be
detected by high-performance liquid chromatography (HPLC).
Electrophysiologic properties of dopaminergic neurons include
spontaneous ﬁring rate of ∼4.5 Hz, prominent anomalous rectiﬁer
currents when hyperpolarized and irregular but unique spike
waveforms of action potentials [13–15].
Finally, it is important to note that various groups of DA neurons
show differences in the susceptibility to the neurodegenerative
process that underlies PD. Speciﬁcally DA neurons of the A9 region
of the substantia nigra are the most susceptible cell type in PD,
compared to DA neurons from the A10 region [16–18]. Interestingly,
the expression of the transcription factor Pitx3 may coax the cells
towards a speciﬁc A9 DA neuronal phenotype [19], whereas Nurr1 in
general promotes the differentiation to a dopaminergic phenotype
[20].
2. Animal models of PD and neurodegeneration
One of the most sought after approaches to study disease
mechanisms in PD has been to develop animal models of the disorder.
Both neurotoxicant and transgenic models of PD have been generated
and characterized with the aim of achieving this goal [21,22]. The
main neurotoxicants that have been used to induce models of PD
include 6-hydroxydopamine (6-OH), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), and various pesticides including paraquat
(PQ) and rotenone. All of these have been shown to induce nigro-
striatal cell death in rodent and non-human primates (for review
[22]). Each of these models has their strengths and weaknesses, but
none fully model the disease.Table 1
Summary of human cell culture models in PD research.
Cell line/source Examples Characteristi
Non-patient speciﬁc human cell lines
Human neuroblastoma cell lines SH-SY5Y, SK-N-MC, SK-N-BE Expression o
differentiatio
Embryonic carcinoma cell line NTera-2/NT2 line, hNT (or LBS) Under co-cu
DAT, Nurr1,
Immortalized human embryonic
mesencephalic cells
LUHMES, ReNcell VM NSCs LUHMES: ex
maintain ph
First generation models of patient-speciﬁc cell lines
Cybrid cell lines Reduced com
ﬁbrillar and
Primary human ﬁbroblasts PINK1-deﬁcient ﬁbroblasts Upregulation
activity, incr
Stem cell models
Human embryonic stem cells Upon optimi
DA release a
Human embryonic and adult neural
stem cells
Expression o
Human mesenchymal stem cells Overall TH e
Pitx3, Pax2,
Human induced pluripotent stem cells TH expressioThe discovery of disease-causing genes and susceptibility factors
for PD [23,24] led to great hope that animal models based on these
discoveries would lead to ideal models for the disease, and in fact
numerous transgenic and knock-out mice models aimed at modeling
PD have been engineered over the last decade. However, aside from a
limited number of alpha-synuclein mouse models, most of these
transgenic lines only show subtle physiologic, neurochemical, or
pathological manifestations that could be said to mirror certain
aspects of PD [25–27]. Because of this, a novel line of researchwhich is
now emerging is the combination of genetic models with the adminis-
tration of toxicants (model fusion) to accelerate and amplify beha-
vioral and pathological features of neurodegeneration of PD and to
study gene–environment interactions [28]. Of course, one limitation
to any complex animal model, particularly vertebrate models, is that
they are usually not amenable to high-throughput screening for drug
discovery.
For all of these reasons, in this review we will focus on the current
and evolving state of cell lines that can be used both for research
on PD disease mechanisms and drug discovery. As dopaminergic
nigrostriatal degeneration is one of the hallmarks of PD (Table 1), we
will center this review on those cell models that can be best used to
study this feature of the disease. There are some very exciting new
advances in the development of cellular models that have the
potential to revolutionize the research landscape in PD.
3. Non-patient speciﬁc human cell lines
Although tissue culture models of disease mechanisms have their
experimental limitations, they have some signiﬁcant advantages over
animal models of disease, particularly in that they can be human
genome-based and allow for the direct investigation of pathophys-
iological characteristics in a far less time and less labor intensive
manner. Not only can experiments be more rapidly performed, but, as
noted above, techniques can even be developed for high-throughput
screening of therapeutic compounds. To study the function of proteins
that may be responsible for neurodegeneration, for example, tissue
culture systems are easily amenable for gene manipulation such as
over-expression of proteins of interest or speciﬁc knockdown of
certain proteins to study their functional consequences. In this article
we will ﬁrst discuss those cellular models that are not based on stem
cell biology. We will then review various stem cell models and
conclude with an overview about the emerging techniques and the
use of induced pluripotent stem cells (iPSCs).cs References
f TH, dopamine D2 and D3 receptors, DAT, and VMAT2 upon
n with RA and TPA (ref. 31)
[29–34]
lture with PA6 cells expression of dopaminergic markers AADC,
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pression of TH and DAT after in vitro differentiation, do not
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vesicular inclusions after prolonged culture conditions
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One of the most widely used cell lines for modeling certain aspects
of neurodegeneration and neurotoxicity in relation to PD is the human
neuroblastoma cell line SH-SY5Y line (ATCC# CRL-2266). These cells,
which were originally derived in 1970 from a metastatic neuroblas-
toma, have moderate levels of dopamine beta hydroxylase activity.
For many researchers, this cell-line has represented a favored starting
point when a tissue culture model system is desired. Currently, a
variety of other neuroblastoma cell lines are available as well,
including the SK-N-MC (ATCC# HTB-10), SK-N-SH (ATCC# HTB-11),
and SK-N-BE (ATCC# CRL-2271) cell lines. All these lines can be
differentiated with retinoic acid (RA) or the phorbol ester, 12-0-
tetradecanoyl-phorbol-13-acetate (TPA), to neuron-like cells with
respect to morphological and biochemical criteria [29,30]. Phenotypic
differences in differentiated SH-SY5Y cells are seen depending on the
differentiation conditions. For example, when RA (10 μM for 3 days)
treatment is followed by TPA (150 nM for 3 days) administering for a
6-day period , these cells express dopaminergic markers such a TH,
dopamine D2 and D3 receptors, DAT, and VMAT2. On the other hand, a
differentiation protocol using only RA shows only minimal expression
of the above mentioned markers, but high expression of VMAT2 [31].
Several pathways have been studied to characterize the effects of RA-
induced neuronal differentiation. RA activates the PI3K/Akt signaling
pathway [32] as well as the ataxia telangiectasia mutated (ATM)
kinase, which leads to a ATM dependent cAMP response element
binding (CREB) protein phosphorylation. When these pathways are
blocked by inhibitors or RNAi, the cells do not differentiate [33].
One interesting observation regarding the SH-SY5Y cell line is that
there are differences in susceptibility between RA-differentiated and
undifferentiated SH-SY5Y cells when exposed to neurotoxicants. For
example, when cells were exposed to 6-OHDA (25 μM) or MPP+
(1 mM) for 24 h, there were marked differences in cell viability,
toxicity, response to oxidative stress and apoptosis, with the undiffe-
rentiated cells proving to be more susceptible to neurotoxins than the
RA-differentiated cells. These results suggest that undifferentiated
SH-SY5Y cells might be a better cellular model for studying neuro-
toxicity [34].
While the SH-SY5Y human neuroblastoma line has been a very
useful model for PD research, there are certain shortcomings of this
model, including the obvious fact that they are not authentic DA
neurons. Furthermore, depending on the experimental questions,
differentiation regimes with varying concentrations of RA and/or
other agents as well as the passage number of the cells, all need to be
controlled. Finally, it also may be important to compare differentiated
and undifferentiated cells in assays and experiments side by side.
3.2. Embryonic carcinoma cell line
Another cell line that provides a somewhat different approach for
PD research is the NTera-2/NT2 line (ATCC# CRL-1973). This is a
malignant human pluripotent embryonic carcinoma cell line that
shares many characteristics of human embryonic stem cells (hESCs),
but also has characteristics of neuronal progenitor cells [35]. Three
subclones of this cell line exist, but the subclone NT2/D1 is the main
one that has been used for neuronal differentiation with RA. In fact,
this line has been made commercially available as hNT (or LBS)
neurons [36]. While these cells hold promise as experimental models,
they have been disappointing in neurotransplantation studies; for
example, when hNT neurons were grafted into animal models of PD
they failed to induce any major behavioral beneﬁt or substantial graft
survival [37–40] and clinical trials showed overall no signiﬁcant
clinical beneﬁt in patients with stroke [41].
Nevertheless, in vitro the NTera-2 line expresses markers of hESCs
and can be differentiated into DA neurons using a culture differen-
tiation regime and co-culture of PA-6 cells for several weeks (for amore detailed discussion on neuronal differentiation see the section in
this article entitled ‘Human embryonic stem cells, alternative stem
cells and directed differentiation into DA neurons'). This protocol
results in a very high percentage (N80%) of TH-positive cells; these
cells express an impressive variety of dopaminergic markers inclu-
ding AADC, DAT, Nurr1, neurotrophic tyrosine kinase receptor, type 2
(TrkB), neurotrophic tyrosine kinase receptor, type 3 (TrkC), and
GDNF family receptor alpha 1 (GFRA1). Furthermore, these cells show
functional properties of dopaminergic cell lines in that they can
respond to neurotransmitters, and exhibit electrophysiological excit-
ability [42]. This model has primarily been used to understand
neuronal differentiation, but it also has the potential to serve as a
promising system to model dopaminergic dysfunction and
degeneration.
4. First generation models of patient-speciﬁc cell lines for the
study of neurodegeneration in PD
Patient-speciﬁc cell lines are those that not only can be used to
model human disease, but that are also derived directly from tissues
of patients with a speciﬁc disorder.
4.1. Cybrid cell lines
Cybrids are hybrid cell lines resulting from cytoplasmic fusion of
cells that lack mitochondrial DNA (mtDNA) fused with platelet
mtDNA from PD patients. Since mitochondrial function has been
shown to be impaired in PD, speciﬁcally Complex I activity, a cybrid
model of sporadic PD represents one of the ﬁrst patient-speciﬁc
attempts to model aspects of PD at the cellular level [43]. The ﬁrst
group to study cybrid cell lines in this manner compared cybrid
cultures from PD patients and healthy controls. They found that
Complex I (Vmax) in the cybrid cells from the patient group was 20%
less than in those cultures from controls, whereas Complex IV activity
was similar between patients and controls [44]. These results have
been conﬁrmed in other independent studies using different host
cell lines [45–47]. PD cybrids have also been shown to exhibit
enhanced susceptibility to hydrogen peroxide and 1-methyl-4-
phenylpyridinium (MPP+) [44,48,49], as well as an increase in reac-
tive oxygen species (ROS) production and antioxidant enzyme
activities when compared to controls. Remarkably, these PD cybrids
have been reported to spontaneously develop ﬁbrillar and vesicular
inclusions within 3–4 months in culture and exhibit at least some of
the biochemical features of Lewy bodies such as staining for eosin,
alpha-synuclein, and ubiquitin [50–52]. In PD cybrids, a large number
of mitochondria have been found to be enlarged, swollen or pale with
only a few cristae [51].
Taken together, this model promises to provide interesting clues to
the mitochondrial deﬁcits in PD and how they relate to the
neurodegenerative process that underlies the disease [53]. Impor-
tantly, it is one of the few cell lines to actually exhibit some aspects of
an actual parkinsonian phenotype at the cellular level, and it is
surprising it has not enjoyed more widespread use for the study of
disease mechanisms and drug discovery. One reason may be that
there are technical challenges in developing these cell lines.
4.2. Primary human ﬁbroblasts from patients with PD
Derivation of primary human ﬁbroblasts to study disease
mechanisms is another potentially appealing approach to developing
patient-speciﬁc cell lines to model PD, but this approach is limited by
the fact that ﬁbroblasts in long-term culture become senescent; they
may also transform and/or undergo clonal selection. Furthermore, for
the study of neurodegenerative disease, there is always the question
of whether or not results obtained in ﬁbroblasts mirror the patho-
physiological changes in human brain, particularly dopaminergic
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patient-speciﬁc ﬁbroblasts are sparse. Nevertheless, few reports
show that under careful experimental conditions, useful data can be
obtained from these cells in speciﬁc mutation carriers of PD asso-
ciated genes [54,55], suggesting that this line of research has pro-
mise for cellular modeling of PD. For example, gene expression
proﬁles in ﬁbroblasts (i) from patients with PTEN-induced putative
kinase 1 (PINK1) mutations that are known to cause parkinsonism in
humans and (ii) ﬁbroblasts in which PINK1 was down-regulated by
RNAi have been used to understand the function of this protein.
Intriguingly, the alpha-synuclein gene (SNCA) was found to be
upregulated in these models systems and expression of genes that
code for synaptic proteins were increased [54]. In another study,
mitochondrial respiratory function was assessed in a PINK1-
deﬁcient ﬁbroblast line from a patient carrying a homozygousW437X
nonsense mutation. Interestingly, the authors found a lower respi-
ratory activity, enhanced ROS production, and a signiﬁcant decrease
in cytochrome C when the PINK1-deﬁcient cells were compared to
controls [55].
Obviously, a very exciting long-term outcome of this research
utilizing peripheral tissue would be the discovery of gene or protein
expression patterns that differ between patients, including sporadic
cases, and healthy matched controls, and thus provide insights into
disease mechanisms. Furthermore, if this is proved to be the case,
these cells could serve as an easily accessible tissue for biomarker
discovery that could facilitate the diagnosis of sporadic PD.
4.3. Human embryonic mesencephalic cells immortalized using ectopic
myc expression
Another alternative developed towards the goal of obtaining
faithful cellular model for PD is the Lund human mesencephalic
(LUHMES) cell line, which is a clone of the v-myc-overexpressing
tetracycline-dependent human mesencephalic cell line MESC2.10
[56]. Tetracycline down-regulates v-myc expression in this line and
the cells can then be differentiated within 3–4 days into a dopa-
minergic phenotype when cultured in dibutyryl cAMP (cyclic adeno-
sine monophosphate) and glial cell-derived neurotrophic factor
(GDNF). These cells express TH and DAT [57], however, they cells
do not maintain their phenotype after transplantation into the 6-
OHDA rat model of PD [58]. Thus, while they could serve as a cellular
dopaminergic model in vitro, they are probably not be amenable for
neurotransplantation in PD [59].
Another immortalized human embryonic mesencephalic cell line
has recently developed from human fetal ventral mesencephalon
stem cells transduced with v-myc (ReNcell VM NSCs) [60]. This cell
line can also be differentiated to exhibit a dopaminergic phenotype
with expression of TH; however, further characterization of pro-
tein expression and neurophysiologic properties will be necessary to
determine if these cells fulﬁll speciﬁc criteria of dopaminergic
neurons [61]. Interestingly, this cell line was recently used to study
the function of the PINK1 gene [62] as well. In this study, the cell line
was transfected with siRNA targeting PINK1. Subsequently, age-
dependent neurodegeneration was observed with reduced long-term
viability of these human neurons; this effect appeared to be mediated
through a mitochondrial apoptosis pathway [62]. Thus, although
there are limitations, these novel immortalized mesencephalic cell
lines may well provide a promising model for studying disease me-
chanisms related to dopaminergic neurons, though additional studies
are needed to validate these models.
5. Human embryonic stem cells, alternative stem cells and
directed differentiation into dopaminergic neurons
A large body of literature is accumulating on the use of hESCs as a
model for development of diverse cell types, including dopaminergicneurons. From a historical perspective, the major impetus for this
research has been to engineer cells which could be used for basic
studies of neural development and for cell replacement therapy. To
date, however, the value of the system for the study of disease
pathways in PD and for drug discovery has been less well appre-
ciated. On the other hand, the great interest in developing hESCs for
neurotransplantation to treat PD has lead to impressive progress in
developing techniques to transform pluripotent cells into dopami-
nergic neurons, the loss of which represents a central feature of PD.
In general, culture conditions for directed differentiation of embryo-
nic stem cells (ESCs) into dopaminergic neurons have been developed
to mimic the microenvironment present in the developing orga-
nism using speciﬁc culture conditions or genetic manipulation
[19,20,63–68]. Recently, a series of elegant studies have unraveled
molecular codes for the generation of midbrain DA neurons; these
require the temporal and spatial expression of speciﬁc neurotrophic
and signaling factors to orchestrate the correct developmental stages
of differentiation [69–71]. Although TH-positive cells can be gener-
ated under speciﬁc culture conditions, the majority of cells produced
with these techniques have different phenotypes because the cells are
not synchronized; thus cell states range from undifferentiated cells to
various stages of neuroprogenitor cells. A challenge to this approach is
that analysis of cell populations is of limited value if the cells are
largely heterogeneous; methods for single cell analysis or for directing
coordinated differentiation are thus needed.
By co-culturing ESCs with mouse PA-6 cells, Kawasaki and
colleagues ﬁrst reported a stromal cell-derived inducing activity
(SDIA) of unknown signaling factors that promoted a neuronal
dopaminergic phenotype in mouse and non-human primate ESCs
[65,72]. Others have subsequently achieved dopaminergic differenti-
ation in hESCs using different variations of these techniques [73–76].
Modiﬁcations now also include the use of other cell types that show
SDIA such as MS5 stromal cells or Sertoli cell co-culture [75,77].
Protocols have also been developed to avoid co-culture using feeder-
free medium for directed neuro-differentiation into a dopaminergic
phenotype [78]. Neuronal differentiation in these protocols is
achieved by sequential addition of different concentrations of
recombinant growth and signaling factors to the culture media such
as sonic hedge hog (SHH), ﬁbroblast growth factor 8 (FGF8), brain-
derived neurotrophic factor (BDNF), GDNF, or ascorbic acid. For
further detailed review on culture regimes for directed differentiation
of ESCs, refer to reference [59]. In summary, there is a rich literature
on the process of differentiating ESCs into a dopaminergic phenotype,
and this body of work will be hugely beneﬁcial in the development of
cellular models of PD in the future.
5.1. Human embryonic and adult neural stem cells
Neural stem cells (NSCs) that can be isolated from adult and fetal
brain and have the inherent ability to expand and to further
differentiate in all neuronal and glial lineages in vitro. As a result,
they have been of great interest as a source for cell replacement
therapy for disease of the nervous system, including PD. For example,
mesencephalic precursors from rat E12 have been shown to
successfully expand and differentiate into dopaminergic neurons
(18.4% TH-positive neurons) and show functional recovery in the 6-
OHDA rat model [79]. Interestingly, when Studer and collaborators
[80] used the same tissue preparation under similar conditions, but at
a lower oxygen concentration of 3% cell proliferation was promoted,
apoptosis was reduced, and the number of dopaminergic neurons
increased to 56% compared to 18% under environmental oxygen
conditions of 20%. This same group also showed successful expansion
and differentiation of human mesencephalic and cortical precursors
into DA neurons with a percentage of 21% and 7.5%, respectively [81].
However, when in vitro studies performed using this cell type as a
primary source several observations were made. First, the develop-
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brain, and culture conditions of the cells (monolayer vs. neuro-
spheres) greatly affect the efﬁciency of generating speciﬁc DA neurons
from neural precursor cells (NPCs) [82] [as reviewed in [83]]. On the
other hand, others have found only limited ability to expand NPCs and
to differentiate them in vitro into DA neurons [84].
While there are a number of publications on the rodent mesen-
cephalic precursor cell lines using various induction methods
[79,85,86], there are surprisingly few such reports utilizing human
tissue. Liste and co-workers [87,88] induced human forebrain NSC
by overexpression of Basal cell lymphoma-extra large protein
(Bcl-XL) under low oxygen conditions; these cells expressed TH,
Nurr-1, and showed DA release. A recent study focused on ampli-
ﬁcation of human NSCs in suspension spinner ﬂask bioreactors for
transplantation purposes from different brain regions [89,90]. Taken
together, these examples show that fetal and adult NSCs can be
differentiated in vitro into dopaminergic neurons. However, more
studies are needed to optimize culture conditions and differentiation
approaches.
5.2. Human mesenchymal stem cells
Mesenchymal stem cells (MSCs) can be easily obtained from i.e.
bone marrow or umbilical cord tissue [91]. Importantly, they are
multipotent when expanded in culture and have low tumorigenecity
[92]. Several groups have described the isolation and derivation of
mesenchymal cells from olfactory mucosa and conjunctiva [93,94].
Interestingly, the generation of putative dopaminergic cells has been
described using different induction methods with a success rate for
TH-positive neurons between 12.7 and 67% [95–99]. For example,
Dezawa and colleagues [95] have reported achieving a frequency of
41% of potential TH-positive neurons by transfecting MSCs from bone
marrow with Notch intracellular domain and an exposure regime of
forskolin, basic ﬁbroblast growth factor (bFGF), ciliary neurotrophic
factor (CNTF), and GDNF. However the frequency of TH-positive cells
was only 3.9% when GDNF was omitted in the culture medium. A
three-step induction protocol with BDNF, nerve growth factor (NGF),
neurotrophin-3 (NT-3), SHH, ﬁbroblast growth factor 8 (FGF8), and
RA generated 62.1%±5.2 TH-positive cells from a subpopulation of
MSCs, termed marrow isolated adult multilineage-inducible (MIAMI)
cells obtained from donors between 3 and 72 years old [98]. Several
groups have also demonstrated stem cell potency of stromal cells
isolated from human umbilical cord mesenchymal tissue (Wharton's
jelly). Putative dopaminergic neurons have also been derived from
cells isolated from human umbilical cord using neuronal conditioned
media, SHH and FGF8, however the frequency of TH-positive neurons
was about 12.7% [97]. Recently it has been report that, when a
protocol for umbilical cord cells using a cocktail of SHH and ﬁbroblast
growth factors was used, 67% of cells showed expression of TH within
12 days in culture [100,101]. Finally, Fallahi-Sichani and colleagues
[102] have investigated the differentiation of umbilical cord stem
cells, into neuronal cells in medium under serum-free conditions. The
derived neuronal cells expressed genes associated with development
and/or survival of midbrain DA neurons such as engrailed homeobox
1 (En1), engrailed homeobox 2 (En2), Nurr1, Pitx3, paired box gene 2
(Pax2), wingless type MMTV integration site family, Member 1
(Wnt1) and wingless type MMTV integration site family, Member 3a
(Wnt3a).
With respect to patient-speciﬁc stem cells, Zhang and colleagues
[103] have characterized 18 bone marrow-derived MSCs from
patients with PD and compared them to MSCs from normal adult
bone marrow. The authors report that PD-derived MSCs are
phenotypically indistinguishable from normal MSCs and exhibit the
same differentiation potential. Furthermore, PD-derived MSCs differ-
entiate into neuronal phenotype under a 2-week culture protocol
with GDNF and showed a TH expression in 30% of the cells. Takentogether these results are encouraging regarding feasibility of this
approach, but many questions remain to be addressed regarding the
authenticity of neuronal cells differentiated from cell types whose
potency is generally limited to mesodermal derivatives.
6. Derivation of human induced pluripotent cell lines by nuclear
reprogramming
Recently, a major scientiﬁc accomplishment was achievedwith the
demonstration of nuclear reprogramming of adult human somatic
cells into cells that are pluripotent and capable of differentiating to all
three germ layers. Nuclear reprogramming is deﬁned by the erasure of
the established programs of a differentiated somatic cell to a
pluripotent cell type; in the case of production of iPSCs, reprogram-
ming is accomplished via introduction of a set of deﬁned molecular
factors, thus changing and modifying the epigenetic landmarks and
the expression of transcription factors within the cell.
The ﬁeld of human iPSC biology was heralded in late 2007 with
the report of Takahashi and collaborators that iPSCs had been
generated from adult human skin ﬁbroblasts with a combination of
four factors: Oct3/4, Sox2, Klf4, and c-Myc using a retroviral system
[104]. The resulting iPSCs were characterized and shown to express
markers of hESCs and to differentiate to all three germ cell layers in
vitro and in vivo [104]. Concurrently, Yu et al. [105] also demon-
strated successful reprogramming of adult dermal cells with a similar
set of transcription factors OCT4, SOX2, NANOG, and LIN28 with a
lentiviral vector system. Since then, a number of other groups have
successfully generated iPSC lines by introducing two to six factors
into human somatic cells with the outcome of generating cells that
resemble hESCs [106–108]. Other researchers have also focused on
developing strategies to increase efﬁciency of reprogramming by
addition of small molecules, and to obtain reprogramming without
integration of transgenes in both mouse and human somatic cells by
using non-integrating adenoviruses, transient transfection, a piggy-
Bac transposon system, Cre/LoxP-excisable vectors, oriP/EBNA1-
based episomal expression vectors, and direct protein transduction
[109–120].
Although further advances in iPSC technology will be necessary
before they can be used for cellular replacement therapy, work in this
area is likely to advance quickly. For example, Wernig and colleagues
[123] have shown that mouse iPSC derived dopaminergic neurons can
integrate in host brain that results in behavioral improvement in the
6-OHDA rat model.
There is currently great excitement regarding the immediate
potential of nuclear reprogramming as a way to develop new
models for a wide range of diseases, including PD. Indeed, one
group has succeeded in generating multiple iPSC lines from patients
with different disorders that were either complex or inherited,
including one patient with sporadic PD [121]. Another group has
successfully derived iPSC lines from patients with another neuro-
degenerative disorder, amyotrophic lateral sclerosis, and differenti-
ated these cells into functional motor neurons [122]. More recently,
ﬁve somatic cell lines from patients with idiopathic PD have also
been reprogrammed using doxycycline-inducible lentiviruses and in
one sporadic PD cell line a loxP-excisable system was used to pro-
duce viral-free iPSC lines. These lines may potentially allow for
optimal comparisons between cell lines from unaffected and PD
patients; importantly, all PD iPSC lines were able to form TH-positive
neurons [119]. However, no overt differences were noted in the
lines derived from PD patients relative to controls under naïve
conditions [119].
While all of the patient work cited above started with skin
ﬁbroblasts, other somatic cells are also amenable to reprogramming.
For example, it has been reported that hepatocytes, keratinocytes, and
blood progenitor cells can be reprogrammed at a much higher
efﬁciency than dermal ﬁbroblasts [124–126].
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The main potential advantage of iPSCs as a cellular model for
Parkinson's research is that it provides for the ﬁrst time the
opportunity to derive dopaminergic neurons from adult humans
who are affected with idiopathic PD. However, since the cause or
trigger for the disease in the vast majority of “sporadic” cases is
unknown, we believe that a more promising source of tissue would be
cells of patients carrying pathogenic mutations that cause PD since
these individuals have parkinsonism of a known cause, and the cells
will carry that cause with them in their DNA. Such an approach is now
possible, since at least ﬁve monogenic forms of PD have been
described over the last decade; indeed these monogenetic forms of
parkinsonism have proved tremendous insight into pathways that
also might be important for sporadic PD [23]. The two autosomal-
dominant forms are represented by the SNCA gene and the Leucine-
rich repeat kinase 2 (LRRK2) gene. Mutations in both genes can
recapitulate many if not all of the characteristics of the clinical and
pathologic features of sporadic PD [127–130]. Three recessive forms of
PD (Parkin, PINK1, and oncogene DJ-1) typically present with an
earlier onset of disease and exhibit some atypical features of PD [131].
Thus, these genetic forms present a unique opportunity to enhance
the chances of obtaining a phenotype that resembles PD. In this
regard, patients with disease-causing mutations would appear to be
the most promising because the clinical and pathological phenotype
can so closely resemble sporadic PD, thus giving hope that any
ﬁndings can be generalized to the vast majority of patients with non-
genetic forms of PD.
The vision for this novel cellular model of PD is that it could
overcome amajor bottleneck for Parkinson's disease, which is the lack
of a predictive preclinical model that can be used for disease research
and drug discovery. A key goal that is essential for this model to be
deemed successful is the development of a neurodegenerative
phenotype that replicates characteristics of one or more features
that are known to occur in brains of patients with PD. For this reason,
if these cells do not exhibit a spontaneous pathological phenotype
that is different from normal control cell lines, strategies that involve
stressing these cells may be necessary to see if they are more sus-
ceptible to degeneration, and/or more prone to developing PD patho-
logy such as alpha-synuclein aggregation. Pathological signaturesmay
be more easily detected if cells are challenged with suspected
environmental, metabolic or neural activity-based stressors.
As tantalizing as the promise of iPSCs may be, there are still
challenges to be overcome. First, as in hESCs, iPSC differentiation
needs to reach a point where efﬁcient differentiation of midbrain THFig. 1. Simpliﬁed scheme for utility of induced pluripotent stem cells and applications in P
differentiation and the various avenues of downstream applications of this novel cellular mneurons can be accomplished on a large scale. Second, iPSCs like hESCs
are genetically unstable and cells should be used at low passages with
frequent karyotype assessment. Finally, an understanding of the
generation of iPSCs will be important, because confounding factors
may increase survivability due to the acquisition of an embryonic
state by an undeﬁned process which might lead to a lack of a cellular
phenotype. In spite of these limitations, there has been rapid progress
in the generation of iPSCs, with continual improvements, and it
currently appears that iPSCs have the potential to be a true “game
changer.” However, here we are not referring to their use for
neurotransplantation to treat the disease, an approach that is likely
to require many more years to come to fruition, at least for PD, but
rather to their use as tools for studying diseasemechanisms and/or for
drug screenings that could halt or even reverse the clinical symptoms
of PD. In our opinion, the possibility of translation of discoveries born
out of iPSC biology will likely come ﬁrst from their use to replicate
authentic PD in a culture dish. If this can be achieved, it would likely
have a huge impact on the development of disease modifying agents.
In our opinion, this approach has a greater likelihood to beneﬁt
patients in a shorter time-frame than the long sought “cure of PD” that
has been hoped for from cell replacement therapy (Fig. 1).
8. Conclusion
Virtually all of the cellular models described in this review have
made valuable contributions to our understanding of PD or are likely
to do so in the future, and without doubt many have served the
scientiﬁc community well over the years (Fig. 2). Each has its uses and
limitations as summarized above. A number, such as patient-speciﬁc
ﬁbroblasts, immortalized neuroprogenitor cells and stem cell lines
appear to have a great deal to offer, but so far have not been utilized to
their fullest as potential disease models for mechanistic research and
drug screening.
However, each falls short of the vision of providing dopaminergic
cell lines with “authentic” PD, rather than representing “best guess”
models that attempt to simulate the disease. We believe that the
creation of iPSC lines from patients with PD, particularly of a known
genetic cause, have the potential to do this. If these cells do in fact
develop a disease phenotype, it could revolutionize research in PD.
Indeed, it is not unreasonable to hope that the nuclear reprogramming
of patient-speciﬁc tissue could form the foundation of multiple new
lines of research that will give us novel insights about causes of PD by
providing (1) in vitro models to understand mechanisms of PD and
neurodegeneration, (2) in vivo models of neural degeneration in
rodent or non-human primate brain, (3) cellular models for high-
throughput screening of drugs/agents, and in the long-term, (4)arkinson's disease. The scheme depicts the derivation of iPSCs, their further neuronal
odel.
Fig. 2. Overview of human cellular models for Parkinson's disease. Cellular models in this review have been categorized into three groups: neuroblastoma cell lines, immortalized
mesencephalic lines, and stem cells, for which examples are listed.
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